These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1114 related articles for article (PubMed ID: 17958545)
1. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545 [TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
3. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
4. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF. Callera F; Cavenaghi L; de Melo CM Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728 [TBL] [Abstract][Full Text] [Related]
5. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor. Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727 [TBL] [Abstract][Full Text] [Related]
6. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889 [TBL] [Abstract][Full Text] [Related]
7. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718 [TBL] [Abstract][Full Text] [Related]
8. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
9. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related]
10. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358 [TBL] [Abstract][Full Text] [Related]
11. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563 [TBL] [Abstract][Full Text] [Related]
12. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation. Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046 [TBL] [Abstract][Full Text] [Related]
13. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949 [TBL] [Abstract][Full Text] [Related]
14. The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Cytotherapy; 2008; 10(5):507-17. PubMed ID: 18608354 [TBL] [Abstract][Full Text] [Related]
15. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Devine SM; Brown RA; Mathews V; Trinkaus K; Khoury H; Adkins D; Vij R; Sempek D; Graubert T; Tomasson M; Goodnough LT; DiPersio JF Bone Marrow Transplant; 2005 Sep; 36(6):531-8. PubMed ID: 16025152 [TBL] [Abstract][Full Text] [Related]
16. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592 [TBL] [Abstract][Full Text] [Related]
17. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF. Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059 [TBL] [Abstract][Full Text] [Related]
18. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Hogge DE; Lambie K; Sutherland HJ; Benny WB; Dalal B; Currie C; Barnett MJ; Eaves AC; Eaves CJ Bone Marrow Transplant; 2000 Mar; 25(6):589-98. PubMed ID: 10734292 [TBL] [Abstract][Full Text] [Related]
19. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621 [TBL] [Abstract][Full Text] [Related]
20. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]